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Abstract  30 
Pharmacotherapy shows striking individual differences in pharmacokinetics 31 
and pharmacodynamics, involving drug efficacy and adverse reactions. Recent genetic 32 
research has revealed that genetic polymorphisms are important intrinsic factors for 33 
these inter-individual differences. This pharmacogenomic information could help 34 
develop safer and more effective precision pharmacotherapies and thus, regulatory 35 
guidance/guidelines were developed in this area, especially in the EU and US. The 36 
Project for the Promotion of Progressive Medicine, Medical Devices, and 37 
Regenerative Medicine by the Ministry of Health, Labour and Welfare, performed by 38 
Tohoku University, reported scientific information on the evaluation of genetic 39 
polymorphisms, mainly on drug metabolizing enzymes and transporters, during non-40 
clinical studies and phase I clinical trials in Japanese subjects/patients. We anticipate 41 
that this paper will be helpful in drug development for the regulatory usage of 42 
pharmacogenomic information, most notably pharmacokinetics. 43 
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The Project for the Promotion of Progressive Medicine, Medical Devices, and 49 
Regenerative Medicine by the Ministry of Health, Labour and Welfare was established 50 
in 2012. One of the projects that was adopted, "evaluation procedures for the efficacy 51 
and safety of pharmaceuticals that use pharmacogenomics," conducted a non-clinical 52 
study and early-phase clinical trials on investigational drugs, and evaluated the effects 53 
of genetic polymorphisms of drug-metabolizing enzymes and transporters primarily 54 
involved in those trials. This work was conducted at the Graduate School of 55 
Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences, Tohoku University, 56 
in cooperation with the National Institute of Health Sciences and Pharmaceuticals and 57 
Medical Devices Agency. 58 
As a main achievement of this project, we compiled the current scientific 59 
information on genetic polymorphisms, which had been evaluated during these non-60 
clinical studies and phase I clinical drug trials in Japanese subjects/patients, obtained 61 
through this project and scientific papers. This report focuses on the genetic 62 
polymorphisms of drug metabolizing enzymes (cytochrome P450 enzymes among 63 
others) and transporters with reported functional significance and allele frequencies of 64 
1% or higher in the Japanese population, and outlines in vitro procedures for the 65 
evaluation of their functional effects on investigational drugs. This report also 66 
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provides examples of genetic polymorphisms and somatic mutations of proteins 67 
involving drug efficacy or adverse drug reactions. We believe that this information 68 
will be helpful to accelerate future research and continued discussions on drug 69 
development using pharmacogenomic information (e.g., dose adjustment and 70 
avoidance of adverse reactions) in Japan and possibly other East Asian countries. 71 
Furthermore, a guideline from European Medicines Agency describes that 1) a 72 
relevant involvement of a known polymorphic enzyme cannot be excluded (i.e., non-73 
clinical in vitro data predict >50% to be cleared by a single polymorphic enzyme in 74 
vivo), it is advised to genotype the first time substance exposure in phase I clinical 75 
trial, 2) if phase I studies indicate that pharmacogenetics influences the 76 
pharmacokinetics of a drug to a possible clinically relevant extent (i.e., >25% of the 77 
drug is metabolized by a single polymorphic enzyme), this should be reflected in the 78 
design of the Phase II studies. No such a guideline is there in Japan. Since multi-79 
regional clinical trials including Japan have been common nowadays, clear 80 
information on frequent and functional genetic polymorphisms in Japanese population 81 
should be useful to promote the safer attendance of Japanese patients into the trials 82 
(http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/83 
02/WC500121954.pdf). The Graduate School of Pharmaceutical Sciences and Faculty 84 
of Pharmaceutical Sciences, Tohoku University anticipated that this information will 85 
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serve as a scientific basis for discussion to make regulatory guidelines in the future. 86 
 87 
1. Introduction 88 
1.1 Purpose 89 
Individual differences in efficacy and safety of drugs are well known, and 90 
factors affecting these differences can be classified into intrinsic and extrinsic factors. 91 
As listed in the ICH-E5 guideline, extrinsic factors include climate, culture, degree of 92 
drug compliance, and method of conducting or endpoint of the clinical trial, while 93 
intrinsic factors include gender, body weight and height, and polymorphisms of genes 94 
involved in drug metabolism. In recent years, many studies on genetic polymorphisms 95 
in drug-metabolizing enzymes and transporters have demonstrated associations with 96 
drug efficacy and/or adverse drug reactions [1-3]. The use of genetic information 97 
could lead to increased efficacy and decreased adverse reactions. 98 
Drug efficacy can be efficiently demonstrated in clinical trials by excluding 99 
specific patient groups with certain types of genetic backgrounds that are associated 100 
with no or very low efficacy of the drug. For example, some studies showed a linkage 101 
between reduced drug efficacy and decreased activity of metabolizing enzymes due to 102 
genetic polymorphisms [4, 5]. As another example, drug toxicity can be caused by an 103 
elevation in blood/tissue concentrations by a reduction in drug metabolizing enzyme 104 
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or transporter activities by genetic polymorphisms, leading to decreased excretion or 105 
decreased elimination of reactive metabolites [6]. Therefore, the use of information on 106 
genetic polymorphisms related to pharmacokinetics/drug efficacy/adverse drug 107 
reactions could potentially prevent delays in drug development and reduce costs 108 
associated with the onset of serious adverse reactions. 109 
This report aims to present scientific information for evaluation of genetic 110 
polymorphisms (mainly on drug-metabolizing enzymes and transporters) and their 111 
functional effects that can be taken into consideration during non-clinical studies (in 112 
vitro studies using human samples) and phase I clinical trials in the Japanese 113 
population. 114 
 115 
1.2 Scope of Application 116 
This report will present the methodology and important considerations for 117 
referral when pharmaceutical companies obtain information on genetic 118 
polymorphisms and/or assess their functional significance for investigational drugs in 119 
non-clinical studies. These evaluations will be helpful to design phase I clinical trials 120 
in the Japanese population. The scope of this document is limited to exploratory 121 
evaluations of the effects of genetic polymorphisms. The methodologies and 122 
information presented here are based solely on current knowledge, and thus, future 123 
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strategies for drug development should not be limited to this document. 124 
 125 
2. Analysis Methods and Examples of Target Genes 126 
2.1 Analytical Methods for Genetic Polymorphisms 127 
Analytical methods for genetic polymorphisms can be divided into 1) 128 
candidate gene analysis and 2) comprehensive gene analysis. This section briefly 129 
outlines the advantages and disadvantages of the two methods. 130 
 131 
2.1.1 Analysis of Genetic Polymorphisms of Candidate Genes 132 
Enzymes that contribute to investigational drug metabolism can be identified 133 
by non-clinical studies using human hepatocytes, their microsomal, cytosolic, or S9 134 
fractions, or expression systems of each drug-metabolizing enzyme. Cytochrome P450 135 
and glucuronyl transferase are present in these samples (except for the cytosolic 136 
fraction). In addition, a growing number of studies have revealed the involvement of 137 
drug transporters that contribute to the uptake/excretion of drugs into/from the small 138 
intestine, liver, kidney, and other organs. When known drug metabolizing 139 
enzymes/transporters are involved in pharmacokinetics, efficacy, and the safety of the 140 
drug, it is possible to explore novel, related genetic polymorphisms and to evaluate 141 
the effects of the polymorphisms on the metabolism of the investigational drug in 142 
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non-clinical studies; this will allow the importance of these polymorphisms to be 143 
considered in subsequent clinical phase I trials. Genetic polymorphisms associated 144 
with functional changes have previously been reported, especially for major 145 
cytochrome P450s, several conjugating enzymes, and transporters. We can use this 146 
information when selecting genes and their polymorphisms for analysis. 147 
For candidate gene analysis, we can use several methods, including 148 
conventional sequencing (Sanger method) and novel sequencing methods using 149 
highly-efficient sequencers (next generation). For analysis of known genetic 150 
polymorphisms, a number of methods can be used, including the PCR-restriction 151 
fragment length polymorphism (RFLP) method, the allele-specific PCR method, DNA 152 
microarrays (products specialized for pharmacokinetics-related genes), and other 153 
sequencing/PCR/hybridization-based methods [7, 8]. These methods can be selected 154 
based on factors such as the number of samples, adjacent sequences of genetic 155 
polymorphisms, instrument availability, and measurement duration. 156 
Advantages of candidate gene analysis generally include its relatively low 157 
cost, low multiplicity corrections in statistics since it measures limited numbers of 158 
polymorphisms, and the need for a relatively small number of patients. A 159 
disadvantage of this method is that it cannot find associated polymorphisms when 160 
unknown molecules are involved in drug responsiveness. Blood or a buccal swab 161 
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could be used as a source of DNA, for example. 162 
2.1.2 Comprehensive Analysis of Genetic Polymorphisms 163 
Genetic polymorphisms that are involved in drug responsiveness can 164 
sometimes be difficult to determine, such as when unknown drug-metabolizing 165 
enzymes and transporters contribute to pharmacokinetics, efficacy, and adverse drug 166 
reactions. In these cases, it is necessity to search for related genetic polymorphisms 167 
by sequencing exon and/or transcriptional regulatory regions of several candidate 168 
genes or even performing genome-wide association studies (GWAS) for a large 169 
number of genetic polymorphisms. 170 
An advantage of this approach is the possibility of finding genetic 171 
polymorphisms in unknown molecules related to drug responsiveness. The 172 
disadvantages include the high cost and the simultaneous detection of many genetic 173 
polymorphisms that may not cause functional changes. 174 
At the stage of phase I clinical trial, it would be generally difficult to clarify 175 
the gene related to the pharmacokinetics and adverse drug reaction by the 176 
comprehensive analysis of genetic polymorphisms because of a small size of samples. 177 
However, if there is a gene associated with interindividual differences of 178 
pharmacokinetics, the comprehensive analysis can extract the candidates of relevant 179 
SNPs. Then, the in vitro functional analysis can be done as a non-clinical studies. So, 180 
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comprehensive analysis of genetic polymorphisms may be useful in phase I clinical 181 
trial. 182 
2.2 Information on Known Genetic Polymorphisms and Their In Vitro Functional 183 
Analysis 184 
This section describes reported genetic polymorphisms (allele frequencies of 185 
≥1% in the Japanese population) with functional changes (by in vivo or in vitro 186 
studies) and how to evaluate the effects of these genetic polymorphisms on the 187 
metabolic or transport activities of the investigational drug (Table 1). It is noteworthy 188 
that several reports on cytochrome P450s have shown variable effects of genetic 189 
polymorphisms with amino acid changes on enzymatic activities, depending on the 190 
substrate structures [9, 10]. 191 
 192 
2.2.1 Cytochrome P450 193 
Cytochrome P450 is a superfamily of metabolizing enzymes, and functional 194 
effects have been widely reported with genetic polymorphisms. The primary enzymes 195 
that contribute to drug metabolism and are expressed in the liver are CYP1A2, 196 
CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5. 197 
Isoforms with known functional polymorphisms with allele frequencies ≥1% in the 198 
Japanese population, and thus could be examined in clinical trials, are CYP2A6, 199 
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CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 [9, 11-16]. The 200 
enzymes are anchored on the cytosolic side of the endoplasmic reticulum membrane, 201 
and P450 oxidoreductase (POR) is required for their enzymatic activity. It is known 202 
that the activities of some isoforms, such as CYP2C9 and CYP3A4, are elevated by 203 
co-expression of cytochrome b5. This co-expression could be important as it 204 
facilitates the evaluation of enzymatic activity [17]. Functional analysis can be 205 
performed using human liver microsomal fractions, in which genotype was 206 
determined or microsomal fractions expressing recombinant enzymes bearing amino 207 
acid alterations involved in genetic polymorphisms. Peptide sequences of the 208 
membrane-anchored region are usually removed to allow soluble expression in E. coli 209 
[18, 19]. When expressed in yeast [20, 21], insect [13, 22], or mammalian cells [23, 210 
24], the enzymes are usually the membrane-anchored forms. It is important to co-211 
express or add POR in the assay system to ensure enzymatic activity, if cytochrome 212 
P450s are expressed in E. coli or insect cells [13, 25, 26]. Although endogenous POR 213 
can be used in yeast or mammal cell assays, some studies use elevated activity system 214 
by co-expression or addition of POR [21]. Storing microsomal fractions at −80°C or 215 
below is important to sustain enzyme activity of cytochrome P450s [27]. However, it 216 
is known that storage of liver tissues at −80°C can decrease their enzymatic activity 217 
[28]. In addition, an appropriate amount of NADPH or its regenerating system 218 
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(including NADP, glucose-6-phosphate dehydrogenase, and glucose-6-phosphate) 219 
must be present, taking the reaction time into account. Substrates used as positive 220 
controls for the measurement of enzymatic activity would be selected as described in 221 
the following section for each isoform. Omission of NADPH or a component of the 222 
regenerating system is often used as a negative control. Given that other metabolic 223 
pathways can potentially contribute to the reduction of the investigational drug, it is 224 
generally preferable to measure the metabolite production rate by the target metabolic 225 
pathways. However, an assessment of the reduction rate of the investigational drug is 226 
beneficial when evaluating the presence of alternate metabolic pathways, or when 227 
understanding the contribution of the target metabolic pathway to all of the metabolic 228 
pathways of the investigational drug.  229 
In the section below, minor allele frequencies (MAFs) are the approximate 230 
reported values in the Japanese population. 231 
 232 
2.2.1.1 CYP2A6 233 
CYP2A6 contributes to 1–2% of the metabolism of marketed drugs [29] and 234 
there are marked ethnic differences in the frequency of CYP2A6 alleles [30]. Known 235 
functional polymorphisms with allele frequencies of ≥1% in the Japanese population 236 
are as follows: CYP2A6*4 (whole gene deletion, loss of activity, approximately 19% 237 
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in MAF), CYP2A6*7 (1412T>C, I471T and gene conversion of 3'-flanking region, 238 
decreased activity due to reduced protein stability, ~10% in MAF), and CYP2A6*9 (-239 
1013A>G, -48T>G, decreased activity due to reduced gene expression level, ~19% in 240 
MAF) [14, 15]. CYP2A6*4, *7, and *9 are prevalent (10-19%) in Asian populations 241 
but have a lower frequency (0-8%) in Caucasian populations [15, 30, 96]. Nicotine 242 
(cotinine generation) and coumarin (7-hydroxylation) are frequently used as positive 243 
controls for functional analysis of this isoform [31, 32]. 244 
 245 
2.2.1.2 CYP2B6 246 
CYP2B6 contributes to 1–2% of the metabolism of marketed drugs [29]. 247 
Known functional polymorphisms with allele frequencies of ≥1% in the Japanese 248 
population are as follows: CYP2B6*4 (785A>G, K262R, ~9% in MAF), CYP2B6*5 249 
(1459C>T, R487C, ~1% in MAF), and CYP2B6*6 (516G>T, 785A>G, Q172H, 250 
K262R, ~16% in MAF) [33]. In Caucasians, CYP2B6*2, *3, *4, *5, *6, and *7 were 251 
found at variant frequencies of up to 30% [34]. There are reports of elevated protein 252 
expression in CYP2B6*4 and decreased protein expression in CYP2B6*5 and 253 
CYP2B6*6 by in vitro analyses. For CYP2B6*6, decreased activity was observed 254 
against efavirenz, while increased activity was observed for the metabolism of 255 
cyclophosphamide and selegiline [16, 35]. Therefore, it is thought that the functional 256 
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effect of variation depends on the substrate. Efavirenz (8-hydroxylation) and 257 
bupropion (hydroxylation), are frequently used as positive controls for functional 258 
analysis [35]. 259 
 260 
2.2.1.3 CYP2C8 261 
Since the year 2000, CYP2C8 gene polymorphism has been identified in 262 
various races. The CYP2C8*3 allele is the most common in Caucasians 263 
(approximately 13% in MAF) after the wild type CYP2C8*1 allele [36]. Although 264 
genetic polymorphisms that cause functional changes and have allele frequencies of 265 
≥1% were not reported in the Japanese population, CYP2C8*2 (805A>T, I269F, 266 
approximately 16% in MAF among black populations), CYP2C8*3 (416G>A; 267 
1196A>G, R139K; K399R, ~14% in MAF among Caucasians and 2% among black 268 
populations), and CYP2C8*4 (792C>G, I264M, ~6% in MAF in Caucasians) are 269 
known to be associated with decreased metabolic activities [37, 38]. Substrates such 270 
as paclitaxel (6α-hydroxylation) are often used as positive controls for functional 271 
analysis of this isoform [38]. 272 
 273 
2.2.1.3 CYP2C9 274 
CYP2C9 contributes to 15–25% of the metabolism of marketed drugs [29]. 275 
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There are significant ethnic differences in the frequencies of CYP2C9 variants [36]. 276 
CYP2C9*3 (1075A>C, I359L, decreased activity), is a known functional 277 
polymorphism with an allele frequencies of 3% and 6% in the Japanese and Caucasian 278 
populations, respectively [12]. In contrast, CYP2C9*2 (430C>T, R144C), which has 279 
approximately 14% in MAF among Caucasians, is not detected in Japanese. 280 
Diclofenac (4'-hydroxylation) and S-warfarin (7-hydroxylation) are frequently used as 281 
positive controls in the functional analysis [39-41]. 282 
 283 
2.2.1.4 CYP2C19 284 
CYP2C19 contributes to 4–8% of the metabolism of marketed drugs [29]. 285 
Approximately 15-25% of the Japanese population are poor metabolizers of 286 
CYP2C19, whereas the poor metabolizer frequency in Caucasians is less than 5% 287 
[36]. Known functional polymorphisms with allele frequencies of ≥1% in the Japanese 288 
population are as follows: CYP2C19*2 (681G>A, splicing defect, loss of activity, 289 
~29% in MAF), CYP2C19*3 (636G>A, W212Stop, loss of activity, ~12.4% in MAF), 290 
and CYP2C19*17 (-806C>T, increased activity due to increased gene expression, 1% 291 
in MAF) [12]. S-mephenytoin (4'-hydroxylation) is an example of a positive control 292 
for the functional analysis [39-41]. However, the functional effects of these three 293 
genetic polymorphisms result from changes in protein expression levels. Therefore, 294 
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they are not considered to have significantly different effects on metabolism among 295 
substrates. 296 
 297 
2.2.1.5 CYP2D6 298 
CYP2D6 contributes to 20–30% of the metabolism of marketed drugs [29]. 299 
The frequency of CYP2D6 PMs is 5 to 10% in the Caucasian population and less than 300 
1% in the Asian population [12]. Known functional polymorphisms with allele 301 
frequencies of ≥1% in the Japanese population are as follows: CYP2D6*5 (whole gene 302 
deletion, loss of activity, ~6% in MAF), CYP2D6*10 (100C>T and others, P34S and 303 
others, decreased activity, ~37.9% in MAF), and CYP2D6*41 (2988G>A and others, 304 
splicing defect, decreased activity, ~1% in MAF) [12]. The decreased activity 305 
associated with CYP2D6*10 is attributed to a decrease in both expression level and 306 
enzyme activity [9, 42-44]. Although the majority of these polymorphisms has been 307 
detected as a haplotype with CYP2D6*10 (~30% in MAF), sole CYP2D6*36 (gene 308 
conversion with CYP2D7 in exon 9, loss of activity, ~1% in MAF) should also be 309 
taken into consideration [12, 45]. As for CYP2D6*10, it has been reported that ~5% 310 
are independent alleles and 26% are haplotypes as CYP2D6*36-CYP2D6*10 [45]. In 311 
addition, although the frequency is low, it is noteworthy that there are many reported 312 
alleles with functional changes in this isoform: CYP2D6*4 (1846G>A and others, 313 
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splicing defect, loss of activity, ~0.3% in MAF); CYP2D6*21 (2573_2574insC, 267 314 
frame-shift, loss of activity, ~0.6% in MAF), CYP2D6*14 (1758G>A and others, 315 
G169R and others, decreased activity, ~0.3% in MAF), and CYP2D6*18 316 
(4125_4133dupGTGCCCACT, VPT duplication, decreased activity, ~0.5% in MAF) 317 
[9, 12, 46]. Please refer to a review paper for detailed descriptions of these low-318 
frequency CYP2D6 genetic polymorphisms [44]. Bufuralol (1'-hydroxylation) and 319 
dextromethorphan (o-demethylation) are examples of substrates that are often used as 320 
positive controls in functional analysis [39-41]. Furthermore, CYP2D6*3 (2549delA, 321 
frame shift, approximately 1.8% in MAF among Caucasians), CYP2D6*4 (~20.5% in 322 
MAF among Caucasians and 5.7% among black populations), and CYP2D6*6 323 
(1707delT, frame shift, ~1.1% in MAF among Caucasians) are known polymorphisms 324 
associated with loss of enzymatic activity that occur at a frequency of ≥1% among 325 
Caucasians and black populations, but very low frequencies have been reported in 326 
Japanese populations [12]. In addition, a duplication polymorphism, CYP2D6*2 × 327 
CYP2D6*2 (~1.7% in MAF among black populations), leading to an ultra-rapid 328 
metabolizer phenotype has been reported. 329 
 330 
2.2.1.6 CYP3A4 331 
CYP3A4 contributes to 40–50% of the metabolism of marketed drugs [29]. 332 
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Screening in different ethnic populations identified a number of CYP3A4 variant 333 
alleles. Overall, variation of the CYP3A4 genotype may contribute only to a minor 334 
extent or only in rare cases, to the interindividual differences in the CYP3A4 335 
phenotypes. However, there is some evidence that CYP3A4*16 displays reduced 336 
activity, which allele seems to be Asian-specific [47]. CYP3A4*16 (554C>G, T185S, 337 
decreased activity, ~1.4% in MAF), is a known functional polymorphism with an 338 
allele frequency of ≥1% in Japanese [11]. Midazolam (1'-hydroxylation) and 339 
testosterone (6β-hydroxylation) are usually used as positive controls in the functional 340 
analysis [39-41]. Furthermore, since CYP3A4 and CYP3A5 have similar substrate 341 
specificity, it is recommended to use an expression system for each recombinant 342 
enzyme (cells or microsomes). 343 
 344 
2.2.1.7 CYP3A5 345 
CYP3A5*3 (6986A>G, splicing defect, markedly decreased activity, ~76% in 346 
MAF) is a known functional polymorphism with an allele frequency of ≥1% in the 347 
Japanese population [12, 13]. There are significant ethnic differences in the frequency 348 
of CYP3A5*3, with allele frequencies ranging from 0.14 among sub-Saharan Africans 349 
to >0.95 in European populations [48]. Positive controls for the functional analysis of 350 
this isoform are similar to those used for CYP3A4. However, the effect of this genetic 351 
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polymorphism is a marked reduction in protein expression level, so its functional 352 
effect is similar among substrates. 353 
 354 
2.2.2 Glucuronyl Transferase and Other Drug-Metabolizing Enzymes 355 
This section describes genetic polymorphisms with functional changes of 356 
≥1% in MAF in the Japanese population for drug-metabolizing enzymes other than 357 
cytochrome P450. Please see individual references for the functional analysis methods 358 
of each enzyme. 359 
 360 
2.2.2.1 UGT1A1 361 
Glucuronyl transferase, which transfers glucuronic acid to the substrate using 362 
a UDP-glucuronic acid, is a membrane-anchored enzyme that is expressed on the 363 
luminal side of the endoplasmic reticulum. Therefore, its activity generally increases 364 
after adding membrane pore-forming reagents, such as alamethicin, but the 365 
concentration used should be carefully titered. Recombinant UGT proteins are usually 366 
expressed in mammalian cells (e.g., COS-1 or HEK293), and by adding the substrate 367 
and UDP-glucuronic acid, functional studies are performed using microsomal 368 
fractions [49, 50]. Specific reactions of each isoform can be measured using 369 
recombinant UGT protein. However, other metabolic pathways can also contribute to 370 
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the loss of the investigational drug in assays using microsomes from human liver 371 
cells, and thus, it is generally preferable to measure metabolite generation as the 372 
metabolic activity. As a negative control, UDP-glucuronic acid is usually omitted. 373 
UGT1A1 is one of nine types of UGT1A, and is expressed at high levels in the liver. 374 
This enzyme is involved in the metabolism of bilirubin and is known to be a causative 375 
gene for Gilbert’s syndrome [51].  376 
UGT1A1*6 (211G>A, G71R, decreased activity, ~19% in MAF), UGT1A1*28 377 
(-54_-39A(TA)6TAA>A(TA)7TAA, decreased activity due to reduced gene expression 378 
level, ~13% in MAF); and UGT1A1*60 (-3279T>G, decreased activity due to reduced 379 
gene expression level, 26% in MAF [however, about half are linked to UGT1A1*28]) 380 
are known polymorphisms with an allele frequency of 1% or higher in Japanese [12, 381 
52]. UGT1A1*93 (-3156G>A) is known to be mostly in linkage disequilibrium with 382 
UGT1A1*28. The frequencies of UGT1A1*6 and *28 in Caucasians are up to 3% and 383 
39%, respectively [12]. SN-38 (generation of 4-deoxy conjugate), a metabolite for 384 
irinotecan, and estradiol (3-conjugation, also mediated by UGT2B7) are often used as 385 
positive controls in the functional analysis of this enzyme [50, 53]. The functional 386 
influence of both UGT1A1*28 and UGT1A1*60 is derived from altered protein 387 





2.2.2.2 NAT2 391 
N-acetyltransferase 2 transfers the acetyl group from acetyl-CoA to the 392 
substrates and is expressed in the cytosol [54]. The antituberculosis drug, isoniazid, 393 
can be used as a positive control substrate for the functional analysis of this enzyme. 394 
However, although there are reports using environmental chemicals as substrates [55], 395 
in vitro functional analyses with recombinant NAT2 enzyme using isoniazid as a 396 
substrate have not been reported to date. Therefore, in non-clinical studies, the 397 
influence of genetic polymorphisms of NAT2 can be evaluated by assessing the 398 
relationship between the blood concentration ratio of the investigational drug and its 399 
NAT2 metabolite (e.g., area under the curve [AUC] ratio) using blood samples from 400 
dosed patients, and the results of a genetic polymorphism screening of the patients in 401 
the clinical trials. For example, functional changes of NAT2 by genetic 402 
polymorphisms can be evaluated from the ratio of isoniazid and its metabolite 403 
acetylisoniazid, 3 h after a single dose [56] [57]. The genetic polymorphisms show 404 
ethnic differences in enzyme activities; almost 50% of Caucasian are slow acetylators, 405 
whereas the frequency of slow acetylators in Japanese populations is only 10% [58]. 406 
Of all the NAT2 allelic variants that had been identified, 3 variants (NAT2*5, 407 
NAT2*6, and NAT2*7) have been shown to account for the majority of the slow 408 
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acetylator genotypes in Japanese subjects [59]. NAT2*4 is a wildtype allele. NAT2*5 409 
(341T>C, I114T, approximately 1% in MAF), NAT2*6 (590G>A, R197Q, ~21% in 410 
MAF), and NAT2*7 (857G>A, G286E, ~9% in MAF) are decreased activity alleles 411 
with known MAF ≥1% in the Japanese population [12]. Furthermore, the frequency of 412 
isoniazid-induced liver injury is reported to be significantly higher in the low activity 413 
genotypes (homozygotes or compound heterozygotes of NAT2*5, NAT2*6, and 414 
NAT2*7) [60, 61]. 415 
 416 
2.2.2.3 GSTM1/GSTT1 417 
These enzymes belong to the glutathione transferase group. The reduced form 418 
of glutathione is transferred to the electrophilic compounds (e.g., reactive 419 
metabolites), which contributes to reductions in, for example, oxidative stress [62]. 420 
GSTM1*0/GSTT1*0 (both are whole-gene deletions), which cause loss of 421 
activities together with GSTM1 and GSTT1, are known polymorphisms with an allele 422 
frequency of ≥1% in Japanese populations [12]. The allele frequencies in Japanese 423 
subjects are approximately 50% for both GSTM1*0 and GSTT1*0. In contrast, the 424 
frequencies of GSTM1*0 and GSTT1*0 in Caucasians are 53% and 20%, respectively 425 
[12]. An in vitro functional analysis for metabolic activities of these alleles is 426 




2.2.2.4 TPMT 429 
Thiopurine methyltransferase (TPMT) is a cytosolic enzyme that transfers the 430 
methyl group from S-adenosylmethionine to substrates [63]. As a functional analysis 431 
method, wildtype and variant-type enzymes are expressed in mammalian cells (COS-1 432 
or COS-7). Then, substrate and S-adenosylmethionine are added to the cytosolic 433 
fraction, and activity is measured [64, 65]. In addition, red blood cell lysates from 434 
peripheral blood, as an enzyme source, are also frequently used with 6-435 
mercaptopurine as a substrate to determine the metabolic production of 6-436 
mercaptopurine using high-performance liquid chromatography (HPLC)-ultraviolet 437 
(UV) detection [66]. 438 
TPMT*3A (460A>G and 719A>G) was found in European Caucasians, 439 
African-Americans, and Southwest Asians and is the most prevalent allele in 440 
European Caucasians (approximately 5% in MAF), but not detected in Japanese [67]. 441 
TPMT*3C (719A>G, Y240C, ~1% in MAF), which causes decreased activity, is the 442 
most prevalent allele with an frequency of ≥1% in Japanese populations [68]. 443 
Compounds, including 6-mercaptopurine (S-methylation) and 6-thioguanine (S-444 
methylation), are often used as positive controls in the functional analysis of this 445 




2.2.2.5 ALDH2 448 
Aldehyde dehydrogenase (ALDH) is an enzyme that metabolizes aldehyde to 449 
carboxylic acid and is known to metabolize acetaldehyde (an ethanol metabolite) into 450 
acetic acid. It is known to metabolize nitroglycerin [69, 70]. Although few functional 451 
analyses have been reported, some have used recombinant wildtype or variant-type 452 
enzymes expressed in E. coli or insect cells (Sf9) [71, 72]. Approximately 50% of 453 
Japanese have inactive ALDH2 whereas none of the Caucasian show this isozyme 454 
abnormality [73]. 455 
ALDH2*2 (1510G>A, E504K, decreased activity, ~27% in MAF) is a known 456 
polymorphism with an allele frequency of ≥1% in Japanese subjects [73, 74]. 457 
Nitroglycerin (1, 2-dinitro glycerol generation) and acetaldehyde (acetic acid 458 
generation) are commonly used as positive controls in the functional analysis of this 459 
enzyme [71, 72]. 460 
 461 
2.2.3 Drug Transporters 462 
Drug transporters are responsible for the uptake/excretion of drugs into/from 463 
tissues such as small intestine, liver, and kidney. Generally, a drug can be a substrate 464 
of multiple transporters, and in many cases, one transporter is not rate-limiting for 465 
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drug clearance. In addition, transporter functions sometimes affect tissue 466 
concentrations of the drug more strongly than they do blood concentrations. 467 
Therefore, the functional significance of transporter genetic polymorphisms is often 468 
difficult to assess, and thus, many transporter polymorphisms await establishment of 469 
their clinical significance, including ABCB1 (P-gp) polymorphisms. Therefore, 470 
smaller numbers of functionally significant genetic polymorphisms have been 471 
established compared with those of metabolizing enzymes. However, evaluation of the 472 
investigational drugs that become substrates for the following two transporters is 473 
worthwhile, since highly frequent and functionally significant genetic polymorphisms 474 
were reported in the Japanese population [75]. 475 
 476 
2.2.3.1 OATP1B1 (SLCO1B1) 477 
Organic anion transporting polypeptide (OATP)1B1, encoded by SLCO1B1, 478 
is primarily expressed in the basolateral (basal) membrane of hepatocytes and 479 
facilitates the transport from the blood into cells of organic compounds with an 480 
anionic state at physiological pH [76]. Wild and variant-type transporters can be 481 
expressed in mammalian cells (e.g., HEK293 and HeLa), and are used to determine 482 
the initial velocity of transporting substrates into cells as an in vitro functional 483 
analysis system [77, 78]. 484 
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The alleles 521T>C (V174A, decreased expression and activity, 485 
approximately 13.9% in MAF, named OATP1B1*5) [12] and 388A>G (N130D, 486 
increased activity, ~66.7% in MAF, OATP1B1*1b) [79] are known polymorphisms 487 
with an allele frequency of ≥1% among Japanese populations. The 521T>C is in 488 
linkage disequilibrium with 388A>G, and they form haplotypes (OATP1B1*15 and 489 
OATP1B1*17), especially in Japanese subjects [79]. Many clinical studies have 490 
reported significantly increased blood concentrations of most OATP1B1 substrates in 491 
521T>C (OATP1B1*5, OATP1B1*15, OATP1B1*17) carriers. However, a significant 492 
decrease or tendency toward decrease in the blood concentrations of some OATP1B1 493 
substrates was observed in OATP1B1*1b (bearing only 388A>G, 46.9% in MAF) 494 
carriers [80]. The allele frequencies of “OATP1B1*5, OATP1B1*15, OATP1B1*17” 495 
and OATP1B1*1b vary between races; approximately 16% and 25% in Caucasians and 496 
5% and 76% in African populations, respectively [12]. The 388A>G is assumed to 497 
cause elevated transporting function via increased OATP1B1 protein expression, 498 
because increased protein expression was detected with an increased number of 499 
388A>G alleles in human liver, but no change was observed in the net transporting 500 
activity. [81]. Estrone 3-sulfate and pitavastatin, for example, are often used as 501 
positive controls in functional analysis [82]. The substrate selectivity of OATP1B1 is 502 
known to be similar to that of OATP1B3 and much overlap is observed for both 503 
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transporter substrates. In addition, as mentioned previously, the functional effect of 504 
the 388A>G could be derived from increased protein expression levels, so that its 505 
functional effect is probably similar among substrates. 506 
 507 
2.2.3.2 ABCG2 (BCRP) 508 
The ATP-binding cassette transporters transport substrates from cells using 509 
ATP as an energy source. Breast cancer resistance protein (BCRP), encoded by 510 
ABCG2, is a multi-drug resistant transporter expressed in the canalicular (apical) 511 
membrane of the bile duct, small intestine, and rectum [83]. As in vitro functional 512 
assay systems, wild and variant-type transporters are expressed in mammalian cells 513 
(e.g., HEK293), and the velocities of substrate accumulation into the cells are 514 
compared. Another method utilizes the expression of recombinant wild and variant-515 
type transporters in polarized cells (such as Caco-2), and the flux ratios [i.e., the 516 
permeability of the investigational drug from the apical side (A) to the basal side (B) 517 
and the permeability of the drug in the opposite direction (from B to A) are measured 518 
and expressed as a ratio (B to A/A to B)] are compared between the expressed cells. In 519 
this method, a correction using the flux ratio of non-expressing cells is applied to 520 
calculate the net flux ratio [(flux ratio of expressing cells)/(flux ratio of non-521 
expressing cells)]. The third method uses assays that compare the velocity of substrate 522 
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accumulation into vesicles expressing wild and variant-type transporters [84]. 523 
The allele 376C>T（Q126X, loss of activity, ~1% in MAF) and 421C>A 524 
(Q141K, decreased expression and activity, ~31% in MAF) are known polymorphisms 525 
with an allele frequency of ≥1% among Japanese populations [12, 85]. The allele 526 
frequency of 421C>A in Japanese subjects is about 3-fold higher than that in 527 
Caucasians (11%) [12]. Estrone 3-sulfate and sulfasalazine, for example, often used as 528 
positive controls in the functional analysis. Estrone 3-sulfate is also a substrate of 529 
OATP1B1. The functional effect of the 376C>T polymorphism is based on the loss of 530 
protein expression, so its functional effect is considered similar among substrates. 531 
 532 
2.2.4 Efficacy or Adverse Drug Reaction-Related Molecules 533 
Genetic polymorphisms can potentially have an influence on the efficacy or 534 
safety of drugs, where amino acid substitutions or altered expression levels of 535 
molecules related to efficacy or adverse drug reactions are observed. Please refer to 536 
the appropriate papers for specific functional analyses, since the methods vary for 537 
each molecule. As examples, two cases are described in the following section. 538 
 539 
2.2.4.1 EGFR/K-RAS 540 
Recently, tyrosine kinase inhibitors and antibodies against epidermal growth 541 
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factor receptor (EGFR) have been developed for the treatment of various cancers, and 542 
somatic mutations of EGFR and its downstream molecules are reported to be 543 
associated with the drug’s efficacy. For example, patients with L858R or deletion of 544 
exon 19 (variations of the tyrosine kinase domain, collectively reported to account for 545 
85% of mutations) of EGFR, showed higher response rates to gefitinib [3, 86]. K-546 
RAS, an intracellular signal transduction molecule of EGFR, is also known to have 547 
somatic mutations that alter the glycine at codon 12 or 13, which is associated with 548 
low efficacy of cetuximab and panitumumab (low response rates and short overall 549 
survival time) [87, 88]. These acquired mutations are only detected in tumor cells (in 550 
somatic cell lineages), and thus are not detected in leukocyte-derived genomic DNA 551 
in the blood. It is noteworthy that use of a highly sensitive and specific detection 552 
method is important, because the percentage of the cells bearing the mutations are 553 
sometimes very low [89]. 554 
 555 
2.2.4.2 HLA 556 
Some types of human leukocyte antigens (HLAs) are known to be related to 557 
specific drug-induced severe cutaneous adverse reactions (SCARs) and hepatotoxicity, 558 
which are believed to be idiosyncratic. For example, HLA-B*58:01 is associated with 559 
allopurinol-induced SCARs, and HLA-B75 (for example, HLA-B75*15:02 or HLA-560 
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B75*15:11) and HLA-A*31:01 are associated with carbamazepine-induced SCARs 561 
[90]. These data suggest that HLA molecules are off-targets of these drugs. In fact, 562 
carbamazepine and oxypurinol, an allopurinol metabolite, were suggested to bind to 563 
HLA-B75 and HLA-B*58:01 proteins, respectively; these bindings are known to 564 
induce cytotoxic T cell activation [91, 92]. 565 
 566 
3. Points to Consider when Designing Phase I Clinical Trials, Based on the 567 
Results of the Non-Clinical Studies 568 
 When the drug is metabolized by a single enzyme, the metabolism will be greatly 569 
influenced by its genetic polymorphisms. In such cases, functional evaluation of 570 
the genetic polymorphisms for the investigational drug through the methods 571 
described in this paper is of general importance. However, in the case of multiple 572 
enzyme involvement in the investigational drug metabolism, the effect of genetic 573 
polymorphisms in one metabolizing enzyme will be limited. 574 
 In some cases, care must be exercised when other drugs are co-administered. 575 
Where one metabolic pathway is affected by genetic polymorphisms and the other 576 
is inhibited by a co-administered drug (i.e., drug interaction), safety issues need 577 
to be considered [93, 94]. In such cases, functional evaluation of genetic 578 
polymorphisms using the methods described in this report will be important. 579 
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 The frequencies of several genetic polymorphisms are known to show ethnic 580 
differences. During drug development, it is important to consider the allele 581 
frequency of genetic polymorphisms in each ethnicity when such genetic 582 
polymorphisms are considered to have an effect on pharmacokinetics, efficacy, or 583 
the safety of the investigational drug. In general, however, the differences in 584 
allele frequencies between adjacent populations, such as within Europeans or East 585 
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Table 1.  Major genetic polymorphisms of drug-metabolizing enzymes and transporters in Japanese populations 1127 
Gene Allele Locations Activity Allele frequencies References 
  Nucleotide changes Amino acid 
changes 




*4 gene deleted   None 0.19 0 0.009 [15, 95, 96] 
*7 1412T>C, gene conversion in 
the 3' flanking region  
I471T 
Decrease 
0.098 0 0 
[15, 95, 96] 
*9 -1013A>G, -48T>G TATA box Decrease 0.19 0.08 0.085 [15, 95, 96] 
CYP2B6 
*4 785A>G K262R Change 0.093 0.040 0.000 [33, 35] 

















0.267-0.29 0.050-0.250 0-0.330 






0.108-0.128 0-0.004 0-0.060 
[12, 98, 100] 
*17 -806C>T; 99C>T I331V  Increase 0.011 0.188 0.235 [12} 
CYP2D6 
*5 gene deleted   None 0.041-0.072 0.016-0.082 0.028-0.107 [101-103] 
*10 100C>T, 1661G>C, 4180G>C P34S, S486T Decrease 0.333-0.408 0.001-0.080 0.019-0.086 [101-103] 
*41 -1584C, -1235A>G, -740C>T, -
678G>A, CYP2D7 gene 






























0.09-0.13 0.30-0.39 0.36-0.45 
[12, 111, 
112] 




0.12 0.28-0.33 0.28-0.32 
[112, 113, 
115] 
NAT2 *5 341T>C I114T Decrease 0.014 0.448 0.342 [12, 60, 61] 
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*6 590G>A R197Q Decrease 0.205 0.283 0.213 [12, 60, 61] 
*7 857G>A G286E Decrease 0.088 0.018 0.063 [12, 60, 61] 
GSTM1 *0 (null) gene deleted   None 0.501 0.529 0.266 [6, 12] 
GSTT1 *0 (null) gene deleted   None 0.496 0.197 0.231 [6, 12] 
TPMT *3C 719A>G Y240C Decrease 0.008-0.028 0.017-0.080 0.024-0.076 [65, 68, 116] 
ALDH2 *2 1510G>A E504K None 0.267 0 0.002 [69, 72, 73] 
SLCO1B1 





0.139 0.161 0.048 





0.313 0.105 0.027 
[12, 118, 
119] 
 376C>T Gln126Stop None 0.009-0.017 0 0 [83, 118] 
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